Ajanta Pharma Confirms Non-Applicability as Large Corporate Entity Under SEBI Framework
Ajanta Pharma Limited has confirmed to stock exchanges that it does not qualify as a Large Corporate Entity under SEBI's debt securities framework. The company reported nil outstanding borrowings as of March 31, 2026, and maintains a CARE A1+ credit rating, demonstrating strong financial position and regulatory compliance.
*this image is generated using AI for illustrative purposes only.
Ajanta Pharma Limited has officially confirmed to BSE and NSE that it does not qualify as a Large Corporate Entity under the SEBI regulatory framework for debt securities issuance. The confirmation was made in reference to SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, which governs fund raising through debt securities by large entities.
Regulatory Compliance Disclosure
The pharmaceutical company submitted its formal disclosure on April 1, 2026, through Sr. VP – Legal & Company Secretary Gaurang Shah. The communication addressed both major stock exchanges where the company's shares are listed, ensuring comprehensive regulatory compliance.
Financial Position Details
Ajanta Pharma provided detailed financial information as part of its regulatory disclosure:
| Parameter | Details |
|---|---|
| Outstanding Borrowings (March 31, 2026) | Nil |
| Credit Rating | CARE A1+ |
| Rating Agency | CARE Ratings Limited |
| Designated Stock Exchange for Fines | NSE |
SEBI Framework Context
The SEBI circular establishes specific criteria for identifying Large Corporate entities and mandates certain borrowing requirements through debt securities. Under this framework, entities classified as Large Corporates must meet mandatory borrowing thresholds through debt markets. The regulation also stipulates that beginning from FY 2022, any shortfall in mandatory borrowing through debt securities would attract a fine of 0.20% of the shortfall amount, levied by stock exchanges at the end of each two-year block period.
Corporate Governance Compliance
By confirming its non-applicability status, Ajanta Pharma demonstrates proactive regulatory compliance and transparent corporate governance practices. The company's nil outstanding borrowings position and strong credit rating reflect its financial stability and prudent capital management approach.
The formal disclosure ensures that investors and regulatory authorities have clear visibility into the company's status under the SEBI debt securities framework, maintaining transparency in corporate communications and regulatory adherence.
Historical Stock Returns for Ajanta Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.91% | -3.08% | -6.77% | +16.39% | +6.64% | +139.46% |
Will Ajanta Pharma's zero borrowing strategy limit its ability to fund future expansion plans or acquisitions in the competitive pharmaceutical market?
How might Ajanta Pharma's capital structure evolve if it grows beyond the Large Corporate Entity thresholds in upcoming years?
Could Ajanta Pharma's debt-free status provide a competitive advantage in potential M&A scenarios within the pharma sector?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
